Results 31 to 40 of about 8,187 (238)
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol [PDF]
In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB).
G. Bianco +11 more
semanticscholar +2 more sources
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj +1 more source
Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei [PDF]
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria.
Bart J., Currie +11 more
core +1 more source
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019).
James A. Karlowsky +9 more
doaj +1 more source
The solution to drug resistance of Gram-negative bacteria – Cefiderocol [PDF]
Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
Jastrzębska, Ilona +4 more
core +3 more sources
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia ...
Dee Shortridge +3 more
doaj +1 more source
Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel +5 more
doaj +1 more source
: Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant +4 more
doaj +1 more source
: Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert +8 more
doaj +1 more source
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany
: Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen +5 more
doaj +1 more source

